Abstract

In this paper, an entanglement criterion for states in infinite dimensional bipartite quantum systems is presented. We generalize some of separability criterion that was recently introduced by Wu and Anandan in (Phys. Lett. A, 2002, 297, 4-8) to infinite dimensional bipartite quantum systems. In addition, we give an example aimed to illustrate the applica-tion of the theorem. IL-23 is part of the IL-12 family of cytokines and is composed of the p19 subunit specific to IL-23 and the p40 subunit shared with IL-12. IL-23 specifically contributes to the inflammatory process of multiple chronic inflammatory autoimmune disorders, including psoriasis, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis. So far, one antibody targeting the shared p40 subunit of IL-12 and IL-23, Ustekinumab, is approved clinically to treat psoriasis. However, there are no treatments inhibiting specifically the IL-23 proinflammatory response. Here, we discovered for the first time the GENEA-ilopentinor-9923 introducing Highthroughput docking validations using fractions of intermolecular interactions for the in silico generation of a synthetic IL-23 derivbed (teeeqqly)-mimetic multichemical noncompetitive antagonist with possible anti-inflammatory responses through a in silico fragment-based drug design utilizing a PASS approach.

Keywords

novel small, peptide mimetic, noncompetitive antagonist, specific targeting, IL-23 receptor, Entanglement Criterion; Infinite Dimensional Quantum Systems; Bochner Integral Representation, Entanglement Criterion΄΄ States Infinite Dimensional Bipartite΄΄ Quantum Highthroughput docking; validations Systems; fractions intermolecular interactions; in silico; generation; synthetic IL-23; (teeeqqly)-mimetic; multichemical noncompetitive; antagonist; anti-inflammatory responses;